A comparative assessment of safety and tolerability of metoprolol versus carvedilol in patients of chronic stable angina

Megha Bansal*, Manju Gari, Manisha Varshney

INTRODUCTION

Ischemic heart disease (IHD) is a condition where there is an imbalance between myocardial oxygen demand and myocardial oxygen supply. Coronary artery disease is becoming major health concern and has become increasingly prevalent nowadays. The Registrar General of India reported that CHD led to 17% of total deaths and 26% of adult deaths in 2001-2003, which increased to 23% of total and 32% of adult deaths in 2010-2013.1 Angina pectoris is a clinical manifestation characterized by chest pain typically in substernum radiating to left arm, jaw, back lasting for 1-5 minutes and is relieved by rest. Beta blockers are one of the drugs indicated in angina. The aim of the study is to compare safety and tolerability of metoprolol and carvedilol in patients of chronic stable angina.
The favorable effects of carvedilol are provided by its anti-oxidant, anti-inflammatory and its anti-apoptotic activities. Carvedilol prevents lipid peroxidation, modification of oxidation of low-density lipoprotein (LDL) particles, preserves the function of nitric oxide (NO) dependent vasodilatation. In contrast, Metoprolol is a selective β1 receptor blocker, which is devoid of intrinsic sympathomimetic property and membrane stabilizing activity.

METHODS

After taking approval from the Ethics Committee, the study was conducted on 100 patients with 50 patients in each group of metoprolol and carvedilol. The patients who attended cardiology outpatient department in RIMS, Ranchi in the age group of 50-60 years of both sexes with the diagnosis of chronic stable angina were included in the study. The patients who had history of intolerance to beta blockers, patients of variant angina, unstable angina, myocardial infarction, history of alcohol abuse, active malignancy, musculoskeletal disease), myocarditis, primary valve diseases, congenital heart disease, concomitant disease which adversely influence the prognosis and/or impair exercise capacity (e.g. malignancy, musculoskeletal disease), advanced heart block, brady arrhythmias, Raynaud phenomenon, history of mental depression, reversible airway obstruction in patients with chronic lung disease, pregnant women, lactating mother were excluded from the study.

After assessing the inclusion and exclusion criteria, the patients were randomized into two groups of 50 patients in each group after obtaining the informed consent. The dose of tablet metoprolol was given at a range of 25-50 mg in two divided doses and tablet carvedilol at a range of (3.125-6.25) mg in two divided doses. The dose was decided by the clinician depending on the patient’s disease status. The patients were followed on 24th week with the following investigations CBC, liver function tests, renal functions tests, fasting blood sugar, post prandial blood sugar, HbA1C, serum sodium, serum potassium. The study period was taken for one year from May 2018 to 2019.

Statistical analysis was performed using SPSS software. The t-test was used to compare the demographic profile and clinical data of the subjects. All values were expressed as mean±standard deviation. The results were evaluated at a significance level of p<0.05.

RESULTS

Out of 100 patients taken into the study, 3 lost to follow up in both the groups, and 2 patients in metoprolol group and 4 patients in the carvedilol group discontinued intervention due to change in the disease pattern. Therefore, out of 100 patients 88 patients were analysed at the end of the study.

Table 1: Demographic characteristics of the study group.

| Sex       | Metoprolol | Carvedilol |
|-----------|------------|------------|
| M:25      | M:28       |            |
| F:20      | F:15       |            |
| Mean age  | 55.86±5.86 | 56.45±3.21 |
| Mean weight | 67.56±10.85 | 67.94±9.59 |
| Mean height | 162.22±6.79 | 162.78±7.19 |

M: Male, F: Female.

Table 2: Routine blood investigations.

| Blood parameters      | Metoprolol (mean±standard deviation) | Carvedilol (mean±standard deviation) | P value |
|-----------------------|--------------------------------------|--------------------------------------|---------|
|                       | Baseline | 24th week | Baseline | 24th week |         |
| Hemoglobin            | 11.77±1.28 | 11.87±0.98 | 11.28±1.43 | 11.47±1.29 | NS      |
| Total leucocyte count | 7.59±1.42 | 7.57±1.21 | 7.07±1.46 | 7.08±1.30 | NS      |
| Platelet count        | 305.58±9.45 | 297.72±2.01 | 339.46±13.66 | 339.46±13.66 | NS     |
| Fasting blood sugar   | 116.68±15.08 | 111.66±11.44 | 117.34±21.15 | 113.18±17.83 | NS     |
| Post prandial blood sugar | 153.46±14.46 | 149.38±7.54 | 149.76±18.85 | 141.48±18.07 | NS     |
| HbA1C                 | 6.30±0.61 | 6.44±0.39 | 6.26±0.82 | 6.37±0.69 | NS      |
| Serum sodium          | 138.92±4.95 | 136.76±2.93 | 137.94±1.68 | 137.48±1.33 | NS     |
| Serum potassium       | 3.88±0.61 | 3.82±0.53 | 3.85±0.23 | 3.75±0.18 | NS      |
| Blood urea            | 25.44±4.66 | 24.56±3.41 | 25.58±3.43 | 25.62±3.84 | NS      |
| Serum creatinine      | 0.79±0.22 | 0.76±0.34 | 0.71±0.21 | 0.76±0.13 | NS      |
| Total bilirubin       | 0.67±0.26 | 0.63±0.20 | 0.73±0.33 | 0.76±0.12 | NS      |
| Direct bilirubin      | 0.17±0.06 | 0.18±0.04 | 0.19±0.08 | 0.19±0.05 | NS      |
| SGOT                  | 29.76±11.43 | 27.98±9.78 | 28.2±8.32 | 26.96±7.22 | NS      |
| SGPT                  | 40.62±12.9 | 35.64±11.83 | 42.48±10.67 | 37.98±10.92 | NS     |

NS: Not significant, SGOT: Serum glutamic oxaloacetic transaminase, SGPT: Serum glutamic pyruvic transaminase.
Two groups were compared for baseline characteristics of age, sex, height, weight. Both groups had male predominance. Mean age of the patients in the metoprolol group was 55.8±5.86 and 56.45±3.21 years in the carvedilol group. Average body weight in metoprolol group was 67.56±10.85 and average height was 162.22±6.79 kg. While in carvedilol group average body weight was 67.94±9.59 and average height was 162.78±7.19 kg as shown in the (Table 1).

Routine blood investigations were done in all the patients and showed in (Table 2).

The lipid parameters like total cholesterol, serum triglyceride, LDL cholesterol and HDL-Cholesterol was assessed at the end of 24 weeks among the patients of both groups, it was revealed that, there was no statistically difference between both the two groups at the end of the study at 24th week as compared to baseline, as described in the (Table 3), but however there was non-significant decrease in serum triglyceride in patients on carvedilol at the end of the study.

Tolerability was assessed among the patients in both the groups, which manifested that 9 out of 43 (21%) patients showed side effect with metoprolol whereas 12 out of 45 patients (27%) showed side effect with metoprolol. Headache was more common in patients taking carvedilol whereas fatigue was more common in patients on metoprolol. It is demonstrated in the (Table 4).

| Lipid parameters | Metoprolol (mean±standard deviation) | Carvedilol (mean±standard deviation) | P value |
|------------------|-------------------------------------|-----------------------------------|---------|
| Total cholesterol | Baseline 234.22±18.03 24th week 232.22±16.04 | Baseline 241.52±28.97 24th week 238.36±26.31 | NS |
| Serum triglyceride | 159.8±16.97 Baseline 160.8±11.47 24th week | 160.22±13.32 Baseline 145.78±15.41 24th week | NS |
| LDL-C | 123.4±12.42 Baseline 122.58±14.71 24th week | 125.9±11.32 Baseline 121.7±12.7 24th week | NS |
| HDL-C | 35.28±9.04 Baseline 40.84±9.72 24th week | 35.8±9.43 Baseline 38.7±9.52 24th week | NS |

NS: Nothing significant; LDL-C: Low density lipoprotein cholesterol; HDL-C: High density lipoprotein cholesterol.

**DISCUSSION**

The main aim of treatment of stable angina pectoris is to reduce cardiac work load and oxygen requirements. Beta blockers are one of the important class of drugs indicated for the treatment of stable angina pectoris. They do it by reducing myocardial oxygen demand by inhibiting the increases in heart rate, arterial pressure, and myocardial contractility caused by adrenergic activation. Our study has demonstrated that there was no significant difference between two groups in terms of routine hematological parameters, but there was decrease in serum triglyceride in carvedilol group which was non-significant whereas no change was observed in metoprolol group. The mechanism for these are poorly understood but multiple hypotheses have been put up for above which includes; α1-adrenergic receptor blockade, vasodilatation, reduced oxidative stress, anti-inflammatory activity: Carvedilol is associated with antioxidant activity possibly attributable to stimulation of endothelial NO production or reduced NO inactivation. Carvedilol also inhibits LDL-C oxidation, potentially reducing the accumulation of oxidized LDL-C in vessel walls and subsequent vascular damage. Furthermore, carvedilol has been shown to protect against ROS via scavenging of free radicals, suppression of free radical generation, and prevention of ferric ion-induced oxidation. Furthermore, α1-receptor blockade caused by carvedilol increases the availability of lipoprotein lipase for triglyceride hydrolysis and in liver by modulating TG efflux and cholesterol synthesis, enhances LDL binding to its hepatic receptors. The net result is that serum glucose and triglycerides decrease and HDL-C is increased. It is possible that carvedilol has independently exerted the above effects on lipid profile. In many of the previous studies, it was demonstrated that metoprolol and carvedilol lead to change in lipid and glucose parameters. Furthermore, previous studies were different to our study in terms of studied population, disease condition, administered drugs, and duration of intervention. Longer periods may indicate long-term changes, but the variability of results increases due to changes in patient’s condition, diet, prescribed medications, and lack of compliance.

**CONCLUSION**

In this prospective study comparing the metoprolol and carvedilol ,we propose that, both the drugs have not caused changes in hematological parameters including...
routine blood investigations, HbA1C. Carvedilol has shown improvement in serum triglyceride i.e., better lipid profile than metoprolol, although no derangement of lipid parameters were observed with metoprolol Both the drugs shown good tolerability which is showed by less side effect profile in all the patients.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Gupta R, Mohan I, Narula J. Trends in Coronary Heart Disease Epidemiology in India. Ann Glob Heal. 2016;82(2):307-15.
2. Ford TJ, Corcoran D, Berry C. Stable coronary syndromes: Pathophysiology, diagnostic advances and therapeutic need. Heart. 2018;104(4):284-92.
3. Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens. 2007;25(4):731-41.
4. Fonseca VA. Effects of β-blockers on glucose and lipid metabolism. Curr Med Res Opin. 2010;26(3):615-29.
5. Sharp RP, Sirajuddin R, Sharief IM. Impact of carvedilol on the serum lipid profile. Ann Pharmacother. 2008;42(4):564-71.
6. Ayashi S, Assareh AR, Jalali MT, Olapour S, Yaghooti H. Role of antioxidant property of carvedilol in mild to moderate hypertensive patients: A prospective open - label study. Indian J Pharmacol. 2016;1:372-6.
7. Bell DSH, Bakris GL, Gill MJB. Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. Diabetes, Obes Metab. 2009;11(3):234-8.
8. Ozbilen S, Eren MA, Turan MN, Sabuncu T. The impact of carvedilol and metoprolol on serum lipid concentrations and symptoms in patients with hyperthyroidism. Endocr Res. 2012;37(3):117-23.

Cite this article as: Bansal M, Gari M, Varshney M. A comparative assessment of safety and tolerability of metoprolol versus carvedilol in patients of chronic stable angina. Int J Basic Clin Pharmacol 2020;9:792-5.